Major Limitations of Cardiovascular Risk Scores
Background. Epidemiological studies conducted in extensive population cohorts have led to the creation of numerous cardiovascular risk predictor models. However, these tools have certain limitations that restrict its applicability. The aim behind the following work is to summarize today's best-...
Saved in:
Main Authors: | , , |
---|---|
Format: | Book |
Published: |
Hindawi-Wiley,
2024-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_00e7a85b02da4afb9569b4f2ceb50ed3 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Ibtissam Talha |e author |
700 | 1 | 0 | |a Noureddine Elkhoudri |e author |
700 | 1 | 0 | |a Abderraouf Hilali |e author |
245 | 0 | 0 | |a Major Limitations of Cardiovascular Risk Scores |
260 | |b Hindawi-Wiley, |c 2024-01-01T00:00:00Z. | ||
500 | |a 1755-5922 | ||
500 | |a 10.1155/2024/4133365 | ||
520 | |a Background. Epidemiological studies conducted in extensive population cohorts have led to the creation of numerous cardiovascular risk predictor models. However, these tools have certain limitations that restrict its applicability. The aim behind the following work is to summarize today's best-known limitations of cardiovascular risk assessment models through presenting the critical analyses conducted in this area, with the intention of offering practitioners a comprehensive understanding of these restrictions. Critical analyses revealed that these scales exhibit numerous limitations that could impact their performance. Most of these models evaluate cardiovascular risk based on classic risk factors and other restrictions, thereby negatively affecting their sensitivity. Scientists have made significant advancements in improving cardiovascular risk models, tailoring them to accommodate a wide range of populations and devising scales for estimating cardiovascular risks that can account for all prevailing restrictions. Better understanding these limitations could improve the cardiovascular risk stratification. | ||
546 | |a EN | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
690 | |a Diseases of the circulatory (Cardiovascular) system | ||
690 | |a RC666-701 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Cardiovascular Therapeutics, Vol 2024 (2024) | |
787 | 0 | |n http://dx.doi.org/10.1155/2024/4133365 | |
787 | 0 | |n https://doaj.org/toc/1755-5922 | |
856 | 4 | 1 | |u https://doaj.org/article/00e7a85b02da4afb9569b4f2ceb50ed3 |z Connect to this object online. |